Leerink Swann to Host Novel Cancer Therapeutics Conference

Roundtable Sessions to Feature Healthcare Industry Leaders Discussing Emerging
Oncology Trends and Challenges
NEW YORK--(Business Wire)--
Leerink Swann, the leading healthcare investment banking firm, today announced
it will host a one day conference on novel cancer therapeutics at the Roosevelt
Hotel in New York City on Wednesday, May 20 from 7:30 a.m. to 4:30 p.m.

The conference, chaired by Leerink Swann Biotechnology Analyst Howard Liang,
Ph.D., will feature senior management from companies that are developing novel
therapeutics for cancer, who will discuss the latest advances and challenges
facing the industry. Leading institutional investors, hedge funds and venture
capital firms in healthcare will participate. Panels will also include key
opinion leaders from MEDACorp, Leerink Swann`s proprietary network of almost
30,000 healthcare experts.

Companies involved include but are not limited to:

ARIAD Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma, Inc.
AVEO Pharmaceuticals, Inc.
Boston Biomedical, Inc.
Celgene Corporation
Cephalon, Inc.
Cougar Biotechnology, Inc.
Curis, Inc.
Dendreon Corporation
Infinity Pharmaceuticals, Inc.
Light Sciences Oncology
Medivation, Inc.
Micromet, Inc.
Poniard Pharmaceuticals, Inc.
Proteolix, Inc.
PTC Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
Seattle Genetics, Inc.

"With Leerink Swann`s highly specialized and differentiated focus on the
healthcare sector, we view cancer diagnostics and therapeutics as a critically
important subject for dialogue with key opinion leaders," said John Sullivan,
Director of Research and Healthcare Strategist at Leerink Swann. "Leerink
Swann`s roundtable series has evolved into an essential event for institutional
investors, venture capitalists, hedge funds, banks and company executives to
glean perspective and insights in an unrivaled format. We look forward to a very
productive conference and many lively discussions among our esteemed
participants."

The roundtable conference on novel cancer developments is the latest in a series
of roundtables hosted by Leerink Swann on a range of healthcare topics. For a
list of past Leerink Swann events, please visit
http://www.leerink.com/news--events/past-conferences.aspx.

Accredited media interested in attending the open sessions at the conference
should contact Risa Goldman Burgess or Justin Drake of Schwartz Communications
at 781-684-0770 or by email at leerink@schwartz-pr.com to register for the
event.

About Leerink Swann

Leerink Swann is a healthcare-focused investment banking firm that provides
equity research, corporate finance, strategic advisory, and asset management
services for institutional, life sciences, and high-net-worth clients. Every
year since 2001, Institutional Investor has named Leerink Swann "Best of the
Boutiques" in several healthcare categories. Through its MEDACorp division,
Leerink Swann provides biomedical-consulting services to the institutional
investment community. With an internal team of experts and a dedicated external
network of academic and community healthcare professionals, MEDACorp assesses
the viability of cutting-edge medical technologies, thus giving decision makers
the information they need to perform. Leerink Swann is a member of FINRA/SIPC.
For more information, visit www.leerink.com.

Schwartz Communications, Inc.
Risa Goldman Burgess or Justin Drake
781-684-0770
leerink@schwartz-pr.com

Copyright Business Wire 2009